The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

Sciwind has granted Verdiva the exclusive global rights to develop, manufacture and commercialize the partnered programs outside of greater China and South Korea. Sciwind has retained the rights to ...

About Oral Ecnoglutide (XW004): Glucagon-like peptide-1 (GLP-1 ... including the long-acting GLP-1 peptide analog Ecnoglutide injection (NDA stage), oral GLP-1 peptide Ecnoglutide tablet XW004 ...

This latter finding is particularly noteworthy as unwanted GI impacts are generally the most commonly cited side effects of today’s leading glucagon-like peptide-1 / glucose-dependent ...

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH ... of today's leading glucagon-like peptide-1 / glucose-dependent insulinotropic (GLP-1/GIP) drugs.

This includes a Phase II-ready oral glucagon-like peptide-1 receptor agonist (GLP-1RA) ecnoglutide, a potential first-in-class oral amylin agonist, and a long-acting subcutaneous amylin agonist.

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...